Xinying Shen1, Yong Li1, Fan He1, Jian Kong1. 1. Department of Interventional Radiology, Shenzhen People's Hospital, Shenzhen, Guangdong, People's Republic of China.
Abstract
OBJECTIVE: Hepatocellular carcinoma (HCC) results in high mortality and metastasis. In this study, the effects of long non-coding RNA (lncRNA) CDKN2B-AS1 on the progression of HCC were investigated. MATERIALS AND METHODS: LncRNA CDKN2B-AS1 expression of HCC cancer and adjacent tissues, and HCC cells were detected. Subsequently, CDKN2B-AS1 was overexpressed and silenced in HCC cells to observe the effects of CDKN2B-AS1 on the cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT) of HCC cells by performing cell counting kit-8 (CCK-8), wound-healing, Transwell, and Western blot. The target gene of CDKN2B-AS1 was predicted and verified to be miR-424-5p, whose expression in HCC cells with up- or down-regulation of CDKN2B-AS1 expression was determined. Moreover, the effects of miR-424-5p on cell viability, migration, and invasion and EMT of HCC cells were investigated with miR-424-5p up-regulation or down-regulation, together with overexpression or silencing of CDKN2B-AS1. RESULTS: CDKN2B-AS1 expression was increased in HCC tissues and cells. Silencing of CDKN2B-AS1 suppressed cell viability, migration, invasion, and EMT, while overexpression of CDKN2B-AS1 produced the opposite results. Furthermore, CDKN2B-AS1 was predicted and verified to target miR-424-5p and was confirmed to negatively modulate miR-424-5p expression. Moreover, overexpression of miR-424-5p partially suppressed the previously high cell viability, migration, and invasion, and activated EMT resulted from up-regulation of CDKN2B-AS1, while silencing of miR-424-5p elevated the cellular processes inhibited by silencing the expression of CDKN2B-AS1. CONCLUSION: The present study revealed that high-expressed CDKN2B-AS1 may associate with the progression of HCC by affecting the cell viability, migration, invasion, and EMT of HCC cells by negatively regulating miR-424-5p.
OBJECTIVE: Hepatocellular carcinoma (HCC) results in high mortality and metastasis. In this study, the effects of long non-coding RNA (lncRNA) CDKN2B-AS1 on the progression of HCC were investigated. MATERIALS AND METHODS: LncRNA CDKN2B-AS1 expression of HCC cancer and adjacent tissues, and HCC cells were detected. Subsequently, CDKN2B-AS1 was overexpressed and silenced in HCC cells to observe the effects of CDKN2B-AS1 on the cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT) of HCC cells by performing cell counting kit-8 (CCK-8), wound-healing, Transwell, and Western blot. The target gene of CDKN2B-AS1 was predicted and verified to be miR-424-5p, whose expression in HCC cells with up- or down-regulation of CDKN2B-AS1 expression was determined. Moreover, the effects of miR-424-5p on cell viability, migration, and invasion and EMT of HCC cells were investigated with miR-424-5p up-regulation or down-regulation, together with overexpression or silencing of CDKN2B-AS1. RESULTS: CDKN2B-AS1 expression was increased in HCC tissues and cells. Silencing of CDKN2B-AS1 suppressed cell viability, migration, invasion, and EMT, while overexpression of CDKN2B-AS1 produced the opposite results. Furthermore, CDKN2B-AS1 was predicted and verified to target miR-424-5p and was confirmed to negatively modulate miR-424-5p expression. Moreover, overexpression of miR-424-5p partially suppressed the previously high cell viability, migration, and invasion, and activated EMT resulted from up-regulation of CDKN2B-AS1, while silencing of miR-424-5p elevated the cellular processes inhibited by silencing the expression of CDKN2B-AS1. CONCLUSION: The present study revealed that high-expressed CDKN2B-AS1 may associate with the progression of HCC by affecting the cell viability, migration, invasion, and EMT of HCC cells by negatively regulating miR-424-5p.
Authors: Abbas Dehghan; Joshua C Bis; Charles C White; Albert Vernon Smith; Alanna C Morrison; L Adrienne Cupples; Stella Trompet; Daniel I Chasman; Thomas Lumley; Uwe Völker; Brendan M Buckley; Jingzhong Ding; Majken K Jensen; Aaron R Folsom; Stephen B Kritchevsky; Cynthia J Girman; Ian Ford; Marcus Dörr; Veikko Salomaa; André G Uitterlinden; Gudny Eiriksdottir; Ramachandran S Vasan; Nora Franceschini; Cara L Carty; Jarmo Virtamo; Serkalem Demissie; Philippe Amouyel; Dominique Arveiler; Susan R Heckbert; Jean Ferrières; Pierre Ducimetière; Nicholas L Smith; Ying A Wang; David S Siscovick; Kenneth M Rice; Per-Gunnar Wiklund; Kent D Taylor; Alun Evans; Frank Kee; Jerome I Rotter; Juha Karvanen; Kari Kuulasmaa; Gerardo Heiss; Peter Kraft; Lenore J Launer; Albert Hofman; Marcello R P Markus; Lynda M Rose; Kaisa Silander; Peter Wagner; Emelia J Benjamin; Kurt Lohman; David J Stott; Fernando Rivadeneira; Tamara B Harris; Daniel Levy; Yongmei Liu; Eric B Rimm; J Wouter Jukema; Henry Völzke; Paul M Ridker; Stefan Blankenberg; Oscar H Franco; Vilmundur Gudnason; Bruce M Psaty; Eric Boerwinkle; Christopher J O'Donnell Journal: PLoS One Date: 2016-03-07 Impact factor: 3.240
Authors: Martin Connolly; Richard Paul; Roser Farre-Garros; Samantha A Natanek; Susannah Bloch; Jen Lee; Jose P Lorenzo; Harnish Patel; Cyrus Cooper; Avan A Sayer; Stephen J Wort; Mark Griffiths; Michael I Polkey; Paul R Kemp Journal: J Cachexia Sarcopenia Muscle Date: 2017-12-07 Impact factor: 12.910
Authors: Samar Samir Youssef; Asmaa Elfiky; Mohamed M Nabeel; Hend Ibrahim Shousha; Tamer Elbaz; Dalia Omran; Mohammad Saeed Marie; Mohammad A Elzahry; Amr Abul-Fotouh; Ahmed Hashem; Mohamed F Guda; Ashraf O Abdelaziz Journal: World J Hepatol Date: 2022-08-27
Authors: Seung Wan Son; Ba Da Yun; Mun Gyu Song; Jin Kyeong Lee; Soo Young Choi; Hyo Jeong Kuh; Jong Kook Park Journal: Int J Mol Sci Date: 2021-07-06 Impact factor: 5.923